Clinical aspects of inflammatory bowel disease.
Inflammatory bowel disease (IBD) accompanies its patients throughout life. Current treatment options do not lead to a cure and are accompanied by significant toxicities. Numerous animal models contributed to the understanding of the pathogenesis of the disease and led to the development of novel treatment strategies. Genome-wide association analysis added a novel dimension. Here, we discuss how characterization of mutated genes in animal models supports the identification of future therapeutic targets.
Siegmund
Britta
B
Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Medizinische Klinik I, Gastroenterology/Rheumatology/Infectious Diseases, Germany.
Zeitz
Martin
M
D000818:Animals; D000906:Antibodies / Q000627:therapeutic use; D004195:Disease Models, Animal; D020022:Genetic Predisposition to Disease; D055106:Genome-Wide Association Study / Q000379:methods*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000235:genetics* / Q000378:metabolism / Q000628:therapy*; D053762:Interleukin-12 Subunit p40 / Q000276:immunology; D053759:Interleukin-23 / Q000037:antagonists & inhibitors / Q000276:immunology / Q000378:metabolism; D008954:Models, Biological; D009154:Mutation; D053473:Nod2 Signaling Adaptor Protein / Q000235:genetics
D000906:Antibodies; D053762:Interleukin-12 Subunit p40; D053759:Interleukin-23; C429018:NOD2 protein, human; D053473:Nod2 Signaling Adaptor Protein